A Study of Lasmiditan in Healthy Elderly Participants

Inclusion Criteria:

- Are overtly healthy males or females, as determined through medical history and
physical examination

- Have a body mass index (BMI) of 19.0 to 35.0 kilograms per meter squared (kg/m²),
inclusive, at the time of screening.

Exclusion Criteria:

- Have known allergies to lasmiditan, related compounds, or any components of the
formulation.

- Are persons who have previously received lasmiditan.

- Have a history of, or electrocardiogram (ECG) findings of, clinically significant
bradycardia, heart block, tachy or brady arrhythmias, or have any other abnormality in
the 12-lead ECG that, in the opinion of the investigator, increases the risks
associated with participating in the study.

- Have significant history of or current cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological, or neurological disorders capable of
significantly altering the absorption, metabolism, or elimination of drugs; of
constituting a risk when taking the study medication; or of interfering with the
interpretation of data. appendectomy, splenectomy, and cholecystectomy are considered
as acceptable.

- Show a history of central nervous system (CNS) conditions such as strokes, transient
ischemic attacks, significant head trauma, seizures, CNS infections, migraines, brain
surgery, or any other neurological conditions that, in the opinion of the
investigator, increase the risk of participating in the study.

- Show evidence of active renal disease (e.g. diabetic renal disease, polycystic kidney
disease) or estimated glomerular filtration rate <60 milliliters per minute per 1.73
meter squared (mL/min/m²).

- Have a history of syncope, presyncopy, uncontrolled vertigo, postural dizziness, or at
risk for falls, as judged to be clinically significant by the investigator.